0001628280-24-007711.txt : 20240228
0001628280-24-007711.hdr.sgml : 20240228
20240228175237
ACCESSION NUMBER: 0001628280-24-007711
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240228
DATE AS OF CHANGE: 20240228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbet-Engels Christophe
CENTRAL INDEX KEY: 0001802615
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 24697586
MAIL ADDRESS:
STREET 1: C/O MILLENDO THERAPEUTICS, INC.
STREET 2: 110 MILLER AVENUE, SUITE 100
CITY: ANN ARBOR
STATE: MI
ZIP: 48104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4/A
1
wk-form4a_1709160742.xml
FORM 4/A
X0508
4/A
2024-02-13
2024-02-16
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001802615
Arbet-Engels Christophe
C/O X4 PHARMACEUTICALS INC.
61 NORTH BEACON STREET 4TH FLOOR
BOSTON
MA
02134
0
1
0
0
Chief Medical Officer
0
Stock Appreciation Right
0.921
2024-02-13
4
A
0
180816
0
A
2034-02-13
Common Stock
180816
180816
D
This Form 4 amendment is being filed to correct the number of stock appreciation rights awarded to the Reporting Person on February 13, 2024. The original Form 4 filed on February 16, 2024 inadvertently reported the number of stock appreciation rights awarded as 475,831 due to an administrative error.
The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.
/s/ Adam S. Mostafa, attorney-in-fact
2024-02-28